Zepbound precautions: who shouldn't take it

Before getting into who should avoid Zepbound, it's worth being precise about who the FDA approved it for in the first place, since eligibility and precaution are two different questions that get conflated constantly online. The label's chronic weight-management indication rests on a body mass index threshold, not a subjective sense of "needing to lose weight." A BMI of 30 or above — the clinical definition of obesity — qualifies a patient for Zepbound on that basis alone, with no additional condition required.

Below that threshold, a second pathway exists for the overweight category: a BMI between 27 and 29.9, paired with at least one weight-related comorbid condition, also qualifies. The label names several qualifying conditions explicitly, including hypertension, type 2 diabetes, and obstructive sleep apnea, along with others like dyslipidemia and cardiovascular disease. The condition has to be present and documented — the BMI-27-plus range doesn't qualify on its own without one.

Below a BMI of 27, with no weight-related condition present, Zepbound falls outside its FDA-approved use entirely. That doesn't mean a prescriber can never write the prescription — off-label prescribing happens in medicine — but it does mean the drug's safety and efficacy data, as reviewed and approved by regulators, don't extend to that population, and insurance coverage for that use is essentially nonexistent.

Separately, Zepbound also carries its own distinct FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity, granted as an additional indication alongside the weight-management approval rather than folded into the BMI-based criteria above. That approval reflects a dedicated clinical trial program studying OSA severity outcomes specifically, not just weight loss as a proxy. In every approved use, the label is explicit that Zepbound is meant to be used alongside a reduced-calorie diet and increased physical activity — it's approved as an adjunct to those lifestyle changes, not as a replacement for them.

That last point gets glossed over constantly, but it's written into the approved indication itself, not tacked on as generic advice. A prescriber weighing whether Zepbound is appropriate is meant to be assessing it alongside a patient's actual dietary and activity plan, not as a stand-alone intervention layered on top of no other change. In practice this rarely means a rigid diet plan is required before a prescription is written, but it does mean the clinical trials that established Zepbound's safety and efficacy data were themselves run with lifestyle counseling built into every treatment arm, including placebo — so the effect sizes reported in the label reflect drug-plus-lifestyle-change, not drug in isolation.

Two situations sit in the label's contraindications section outright, meaning Zepbound should not be prescribed at all rather than prescribed with extra monitoring. The first is any personal or family history of medullary thyroid carcinoma, or a diagnosis of Multiple Endocrine Neoplasia syndrome type 2. This isn't a soft caution — it's a hard exclusion built directly into the label's contraindications language, and it applies even if you've never personally been diagnosed with thyroid cancer, as long as it runs in your immediate family.

The second contraindication is a prior serious allergic reaction to tirzepatide itself — anaphylaxis, angioedema, or a comparably severe hypersensitivity response. If you've had that kind of reaction to Zepbound, Mounjaro, or another tirzepatide-containing product before, restarting the same active ingredient carries a real risk of recurrence, and the label treats it as disqualifying rather than something to monitor through.

Pregnancy sits in a related but distinct category: not recommended, rather than formally contraindicated. The distinction matters clinically — weight loss during pregnancy provides no established benefit to the pregnant patient and could plausibly affect a developing fetus, and there isn't enough human safety data yet to rule out risk. If you're pregnant, actively planning a pregnancy, or become pregnant while using Zepbound, the standard guidance is to stop and discuss a transition plan with your prescriber rather than continuing through it.

A history of pancreatitis and regular alcohol use are handled differently again — as caution flags rather than exclusions. Pancreatitis history means a prescriber should weigh that history carefully, watch more closely for early symptoms, and make an individualized judgment rather than defaulting to a blanket no. Regular alcohol use gets flagged because it can compound the gastrointestinal side effects — nausea, vomiting, dehydration — that are already common with tirzepatide, making both harder to manage if they overlap.

Beyond the headline contraindications, Zepbound's "Warnings and Precautions" section covers several other areas that matter for specific patients, even though none of them amount to an outright bar on treatment. The first is acute gallbladder disease. Rapid, substantial weight loss — the kind Zepbound is often prescribed to produce — is independently associated with an increased risk of gallstones and gallbladder inflammation, separate from any direct drug mechanism. Patients who develop symptoms like right-upper-abdomen pain, fever, or jaundice while on treatment should be evaluated for gallbladder disease rather than assuming it's routine GI upset.

The second is hypoglycemia risk when Zepbound is combined with insulin or with sulfonylurea-class diabetes medications. Tirzepatide itself lowers blood glucose, and stacking that effect on top of insulin or a sulfonylurea — drugs that also lower glucose independently — can push blood sugar down further than intended. The label specifically advises considering a dose reduction of the concomitant insulin or sulfonylurea when starting Zepbound, precisely to head off this interaction rather than discover it after a hypoglycemic episode.

Third is acute kidney injury, which the label ties back to the same gastrointestinal side effects that show up on nearly every Zepbound side-effect list — nausea, vomiting, and diarrhea. Those symptoms, if severe or prolonged, can lead to real dehydration, and dehydration is a well-established trigger for acute kidney injury, particularly in people who already have reduced kidney function or are on other medications that affect the kidneys. The practical guidance is straightforward: stay ahead of fluid losses during dose escalation, and don't dismiss unusually persistent vomiting or diarrhea as something to just push through.

Fourth is diabetic retinopathy complications, which applies specifically to people with type 2 diabetes rather than to the general Zepbound population. Rapid improvement in blood glucose control — which tirzepatide can produce quickly — has been associated in the broader GLP-1 and dual-agonist drug class with a temporary worsening of existing diabetic retinopathy, even while the underlying glucose control is genuinely improving. This is a known phenomenon across glucose-lowering therapies generally, not unique to tirzepatide, but it's specifically called out for patients with type 2 diabetes and existing retinopathy, who may benefit from closer eye-health monitoring during the period of fastest glucose improvement.

A fifth item worth knowing about, even though it's more of a practical interaction note than a safety warning in the strict sense: Zepbound delays gastric emptying, which is part of how it produces satiety, but that same mechanism can affect how quickly other oral medications are absorbed. The label calls out oral hormonal contraceptives specifically — because delayed absorption could theoretically reduce their effectiveness, the guidance is to switch to a non-oral contraceptive method or add a barrier method for four weeks after starting Zepbound and for four weeks after each dose increase. Anyone on a narrow-therapeutic-window oral medication should flag it with their prescriber for the same reason, since the timing of absorption, not just the total dose, can matter for how well that medication works.

The thyroid contraindication is the single most consequential item on this whole page, so it's worth explaining where it actually comes from rather than just stating the rule. In animal studies, specifically in rats, tirzepatide produced a dose-dependent and treatment-duration-dependent increase in thyroid C-cell tumors — both adenomas and carcinomas — at plasma exposure levels considered clinically relevant to human dosing. That's not a marginal or ambiguous finding in the rodent data; it was a clear, measurable effect that scaled with both dose and how long the animals were treated.

What's genuinely unresolved is whether that same biology translates to humans. The human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined, and the label says so directly — this isn't a case of regulators hiding uncertainty, it's stated as an open question in the prescribing information itself. Rodent thyroid C-cells are known to be more sensitive to this particular tumor-promoting mechanism than human C-cells are believed to be, which is part of why the human relevance remains genuinely unclear rather than settled in either direction.

Faced with that uncertainty, the label takes the precautionary route: rather than waiting for long-term human carcinogenicity data that doesn't yet exist, it excludes the population already known to carry elevated thyroid cancer risk — people with a personal or family history of MTC, and people with MEN 2, a genetic syndrome that predisposes carriers to MTC among other endocrine tumors. That's why family history counts just as much as a personal diagnosis: MEN 2 and MTC susceptibility can run in families even when a given individual hasn't been diagnosed themselves, and the contraindication is written broadly enough to catch that risk before it becomes a personal diagnosis.

This is also why every version of tirzepatide's prescribing information, and the counseling that's supposed to accompany it, tells prescribers to describe the symptoms of thyroid tumors to patients directly — a lump or mass in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness. None of those symptoms mean something is definitely wrong, but they're specific enough, and the underlying uncertainty serious enough, that patients are meant to know what to watch for and report promptly rather than dismiss.

Everything above reflects the major, most commonly cited flags from Zepbound's current FDA label, organized so they're easier to scan than the full prescribing information document. It is not, and isn't meant to be, a complete individualized risk assessment. A prescribing label is written to cover a broad population; it can't account for the specific combination of medications you're already taking, the exact severity of a past condition, or interactions between two relatively minor factors that only matter when they occur together in one person.

That's the practical reason a full medical history review with a prescriber is described as essential rather than optional, and not just boilerplate caution. Things that don't make a highlight-reel summary like this one — a mild kidney function change from years ago, a medication you take occasionally rather than daily, a family member's diagnosis you didn't think to mention because it seemed unrelated — can be exactly the detail that changes a prescriber's judgment about dose, monitoring frequency, or whether Zepbound is the right choice at all.

The intake process for a GLP-1 or dual-agonist prescription typically involves a structured history: current medications (particularly insulin, sulfonylureas, and other drugs affecting gastric emptying), personal and family cancer history, prior reactions to injectable medications, current alcohol use, gallbladder and pancreatic history, and pregnancy status or plans. Coming to that conversation prepared with accurate, complete answers — rather than assuming a quick summary online covers everything relevant — is the single most useful thing a patient can do before starting.

None of this is medical advice, and nothing on this page should be used to self-diagnose eligibility or self-exclude without confirming with a clinician. If you're unsure whether something in your history matters, the safer default is to mention it and let a prescriber weigh it, rather than deciding on your own that it's probably fine to leave out.